0000000000907959

AUTHOR

F Mocciaro

showing 10 related works from this author

Unusual perforation after balloon dilation in a Crohn's disease patient:report of a case

2011

perforation after balloon dilation
researchProduct

Is splenectomy a treatment option for aseptic abscesses in patients with Crohn's disease?

2009

Splenectomy aseptic abscesses Crohn's disease
researchProduct

Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study

2016

Background and Aims: Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nested case-control study, we aimed to characterise incident cases of cancer in IBD. The role of immunomodulators vs clinical characteristics of IBD as risk factors for cancer was also investigated. Materials and Methods: From January 2012 to December 2014, each IBD patient with incident cancer was matched with two IBD patients without cancer for: IBD type, gender, and age. Risk factors were assessed by multivariate regression analysis. Results: IBD patients considered numbered 44619: 21953 Crohn’s disease \[CD], 22666 ulcerative colitis [UC]. Cancer occurred in 174 patients…

AdultMalemedicine.medical_specialtyPancolitisAdolescentColorectal cancerphenotypeSettore MED/12 - GASTROENTEROLOGIAcancer riskInflammatory bowel disease; cancer risk; phenotype; Adolescent; Adult; Aged; Aged 80 and over; Case-Control Studies; Female; Follow-Up Studies; Humans; Immunologic Factors; Incidence; Inflammatory Bowel Diseases; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasms; Prospective Studies; Risk Factors; Young Adult; PhenotypeGastroenterologyInflammatory bowel diseaseInflammatory bowel disease03 medical and health sciencesYoung Adult0302 clinical medicineRisk FactorsInternal medicineNeoplasms80 and overmedicineHumansImmunologic FactorsProspective StudiesRisk factorProspective cohort studyAgedAged 80 and overbusiness.industryIncidenceSettore MED/09 - MEDICINA INTERNAGastroenterologyCancerGeneral MedicineMiddle Agedmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisLogistic Models030220 oncology & carcinogenesisCase-Control StudiesNested case-control studyMultivariate Analysis030211 gastroenterology & hepatologyFemalemedicine.symptombusinessInflammatory bowel disease; cancer risk; phenotypeFollow-Up Studies
researchProduct

Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy.

2022

Abstract Background Adalimumab is used to treat ulcerative colitis, but additional effectiveness and safety data are needed. Patients and methods This retrospective study considered adults with ulcerative colitis treated with adalimumab at 19 hospitals. Clinical data were collected from the start of treatment, after 2, 6 and 12 months, and at the last visit. Outcome measures of effectiveness were treatment duration, reasons for discontinuation and colectomy. Results We studied 381 patients treated with adalimumab for a median of 12.1 months. Disease activity at the start of treatment was moderate to severe in 262 cases (68.8%) and endoscopic activity was moderate to severe in 339 cases (89.…

musculoskeletal diseasesAdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentEffectivenessYoung AdultInternal medicineAdalimumabMedicineHumansAdverse effectskin and connective tissue diseasesColectomyColectomyAgedRetrospective StudiesReal-world evidenceHepatologybusiness.industryGastroenterologyEffectiveneAdalimumabRetrospective cohort studyInduction ChemotherapyMiddle Agedmedicine.diseaseUlcerative colitisDiscontinuationClinical PracticeTreatment OutcomeUlcerative colitisItalyAdalimumab; Effectiveness; Real-world evidence; Safety; Ulcerative colitisConcomitantColitis UlcerativeFemaleTumor Necrosis Factor InhibitorsSafetybusinessmedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Cyclosporine or infliximab as rescue therapy in severe 2 refractory ulcerative colitis: Early and long-term data 3 from a retrospective observational…

2012

Introduction: About 30–40% of patients with acute severe ulcerative colitis (UC) fail to respond 23 to intensive intravenous (iv) corticosteroid treatment. Iv cyclosporine and infliximab are an ef- 24 fective rescue therapy in steroid-refractory UC patients but up to now it is still unclear which is Q225 the best therapeutic choice in this setting of patients. 26 Methods: We reviewed our series of severe steroid-refractory colitis admitted consecutively in 27 our referral center since 1994 comparing two historical cohort treated with cyclosporine or 28 infliximab. Iv cyclosporine was administered at the dosage of 2 mg/kg and infliximab at the dos- 29 age of 5 mg/kg. The main outcome was the…

infliximabulcerative colitiscyclosporine
researchProduct

COLORECTAL CANCER IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: PRELIMINARY RESULTS FROM AN ONGOING CASE-CONTROL STUDY

2014

Background and Aim:Understanding the risk factors for colorectal cancer (CRC) is crucial to the development of effective strategies for its prevention. meta-analysis and epidemiological studies have already shown that type 2 diabetes mellitus (DM) is associated with an increased risk of CRC and have provided data to support a positive relationship between these diseases. Material and Methods: We retrospectively evaluated 741 consecutive caucasian patients with type 2 DM who underewnt colonoscopic screening cof CRC and followed in our tertiary referrral center in 200-208 for incidence of CRC. Patients were stratified based on gender, age, body mass index (MBI), alchool and NSAIDS assumption,…

Settore MED/18 - Chirurgia GeneraleSettore MED/12 - Gastroenterologiacolorectal cancer diabetes mellitus
researchProduct

Severe cutaneous psoriasis after certolizumab pegol treatment;report of a case.

2009

crohn's diseasePsoriasisCerolizumab
researchProduct

THE ROLE OF CARD15 MUTATIONS AND SMOKING IN THE COURSE OF DISEASE IN A MEDITERRANEAN AREA

2008

. Am J Gastroenterol. 2008 Mar;103(3):649-55. The role of CARD15 mutations and smoking in the course of Crohn's disease in a Mediterranean area. Renda MC, Orlando A, Civitavecchia G, Criscuoli V, Maggio A, Mocciaro F, Rossi F, Scimeca D, Modesto I, Oliva L, Cottone M. Ematologia II Ospedale V. Cervello, Palermo, Italy. AIM: To evaluate the role of CARD15 mutations and smoking in the main events of Crohn's disease (CD). PATIENTS AND METHODS: A total of 182 patients with CD were included in a prospective study in order to evaluate the role of CARD15 mutations and smoking in the main outcomes of disease course: first operation and surgical recurrence. The following variables were evaluated in …

researchProduct

Malattia polmonare cronica nei neonati VLBW: studio di una casistica 2005-2007

2009

Settore MED/38 - Pediatria Generale E Specialisticaneonato VLBW polmone
researchProduct

Biologic therapies versus conventional therapies. A series of Crohn’s disease patients: “a pair-matched study”

2011

infliximab crohn disease
researchProduct